## Mankind Pharma Limited (MANKIND) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Mankind Pharma Limited (MANKIND) is a pharmaceutical company listed on the Indian stock exchanges on May 9, 2023.  The company operates within the Pharmaceuticals & Biotechnology sector and is positioned as a mid-cap player in the Indian pharmaceutical market.  Further details on its specific market niche and competitive landscape are needed for a more comprehensive analysis.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹2,800.00       | Closed at ₹2,800.00, down from the previous close.                 |
| Percentage Change (PChange) | -3.15%          | Significant negative daily price change.                             |
| Pre-Open Activity          | ₹2,907.80       | Opened higher than the previous close, indicating initial buying interest.  |
| Week High                   | ₹2,922.90       | Indicates recent price strength.                                     |
| Week Low                    | ₹1,851.05       | Shows significant price volatility over the week.                    |
| VWAP                        | ₹2,834.73       | Volume Weighted Average Price suggests a slightly higher average trading price. |
| Sector PE                   | 54.51           | Sector Price-to-Earnings ratio.                                      |
| Symbol PE                   | 54.51           | Company's Price-to-Earnings ratio, indicating valuation relative to earnings. |
| Delivery Percentage         | 41.45%          | Relatively high delivery percentage suggests some degree of long-term investment. |
| Market Depth                | Limited Data    | The provided data on market depth is insufficient for a thorough analysis.  More detailed order book data is required. |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the last five quarters, although the figures are unaudited for some quarters.  However, there's a noticeable decline in revenue and profit in recent quarters compared to the previous year.  Further analysis is needed to determine the reasons for this decline.  Key financial ratios (e.g., Return on Equity, Debt-to-Equity) are missing and would significantly enhance the analysis.

| Quarter      | Revenue (₹)     | Expenses (₹)    | Profit After Tax (₹) | EPS (₹) |
|--------------|-----------------|-----------------|-----------------------|---------|
| Q1 FY25 (Jul-Sep 2024) | 263,550         | 186,505         | 63,443                 | 15.04    |
| Q4 FY24 (Apr-Jun 2024) | 249,809         | 192,072         | 51,349                 | 12.09    |
| Q3 FY24 (Jan-Mar 2024) | 223,654         | 169,168         | 45,417                 | 11.34    |
| Q2 FY24 (Oct-Dec 2023) | 242,580         | 184,945         | 48,707                 | 12.16    |
| Q1 FY24 (Jul-Sep 2023) | 251,146         | 189,950         | 47,288                 | 11.80    |


**4. Corporate Actions and Announcements:**

Recent announcements include Qualified Institutional Placements (QIPs), suggesting the company is actively seeking to raise capital.  There are also several "General Updates" announcements, the specifics of which are not provided.  The absence of dividend announcements or other corporate actions needs further investigation.  The provided data lacks detail on the impact of these announcements on the stock price.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 76.50                        | 23.50      | 0.00                | 100.00    |
| 31-Dec-2023  | 76.50                        | 23.50      | 0.00                | 100.00    |
| 31-Mar-2024  | 74.88                        | 25.12      | 0.00                | 100.00    |
| 30-Jun-2024  | 74.87                        | 25.13      | 0.00                | 100.00    |
| 30-Sep-2024  | 74.87                        | 25.13      | 0.00                | 100.00    |

Promoter holding has slightly decreased over the past year, while public holding has increased correspondingly.  This needs further investigation to determine the reasons behind this shift.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The provided CM Daily and Annual Volatility (1.85% and 35.34% respectively) further confirms this.  The risk-reward profile is currently skewed towards higher risk due to the price volatility and recent decline in financial performance.  More detailed risk metrics (e.g., Beta, Sharpe Ratio) are needed for a complete assessment.

**7. Advantages of Buying the Stock:**

* Relatively high promoter holding (though decreasing).
* Presence in a growing pharmaceutical sector.

**8. Disadvantages and Risks:**

* High stock price volatility.
* Recent decline in revenue and profit.
* Limited information on competitive landscape and future growth prospects.
* Insufficient data on debt levels and other key financial ratios.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The recent price decline and high volatility suggest a high risk of further losses in the short term.  Waiting for a clearer trend to emerge is advisable.

* **Medium-term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends on the company's ability to reverse the recent decline in financial performance and provide clarity on the impact of recent corporate actions.  Further investigation into the reasons for the revenue and profit decline is crucial.

* **Long-term (1 year and beyond): Hold (if you have stock), Don't Buy (if you don't).**  Long-term investment requires a more thorough understanding of the company's long-term growth strategy, competitive advantages, and management's ability to execute its plans.  The current data is insufficient to make a strong long-term buy recommendation.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* **Financial Health (out of 10): 4:**  Consistent profitability but recent decline in revenue and profit is concerning.  Missing key financial ratios hinder a complete assessment.
* **Market Performance (out of 10): 3:** High volatility and recent negative price movement.
* **Volatility and Risk (out of 10): 2:** High volatility presents significant risk.
* **Corporate Actions and Governance (out of 10): 6:**  Active fundraising through QIPs is positive, but lack of dividend information and details on general updates is negative.
* **Shareholding Patterns (out of 10): 7:** Relatively high promoter holding, although it's decreasing.

**Analysis Score (out of 10): 6**

* **Completeness and Utilization of Data (out of 10): 6:**  Most data points were used, but some crucial information was missing (e.g., detailed order book, key financial ratios, complete corporate action details).
* **Accuracy and Clarity of Analysis (out of 10): 7:**  Analysis was clear and well-structured, but limited by the incomplete data.
* **Professional Formatting (out of 10): 8:** Report is well-formatted and easy to read.


**11. Professional Recommendation Summary:**

Based on the available data, Mankind Pharma Limited presents a mixed picture. While the company operates in a promising sector and has relatively high promoter holding, recent financial performance has declined, and the stock exhibits high volatility.  Therefore, a cautious approach is recommended.  For short-term and medium-term horizons, a "Don't Buy" recommendation is given unless you already hold the stock, in which case a "Hold" is suggested.  A "Hold" recommendation is also given for the long term, pending further investigation and clarification on the company's future prospects.  More comprehensive financial data and a deeper understanding of the company's competitive landscape are needed to make a more definitive recommendation.
